Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer (Q33598660)

28 July 2017

1 reference

title

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer (English)

1 reference

28 July 2017

1 reference

1 reference

1 reference

1 reference

M M Goldenberg

1

1 reference

28 July 2017

publication date

1 February 1999

1 reference

28 July 2017

published in

Clinical Therapeutics

1 reference

28 July 2017

volume

21

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

309-318

1 reference

Cancer incidence and mortality, 1973-1995: a report card for the U.S.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Recent trends in U.S. breast cancer incidence, survival, and mortality rates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Growth factors and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

1 reference

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988288-0

7 January 2021

10.1016/S0149-2918(00)88288-0

Identifiers

DOI

1 reference

28 July 2017

1 reference